Problems at Hospira plants dog Pfizer and some of its clients

1st November 2017 Uncategorised 0

When Pfizer was preparing to shell out $15 billion for regulatory-challenged Hospira, executives assured investors and regulators that they had the skills to quickly resolve issues at the plants of the sterile injectables specialist. But it has turned out to be a harder job than they anticipated, taking a toll on Pfizer’s earnings and creating serious problems for some of its clients along the way.

More: Problems at Hospira plants dog Pfizer and some of its clients
Source: fierce